Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Diseases (Basel, Switzerland)|November 25, 2018
DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based VaccinesGustavo Cabral-Miranda, Ahmed M Salman, Mona O Mohsen, et al.The Journal of Allergy and Clinical Immunology|December 24, 2019
Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergensFederico Storni, Andris Zeltins, Ina Balke, et al.Allergy|February 5, 2025
Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III TrialStefan Zielen, Jonathan A Bernstein, Gunter J Sturm, et al.Allergy|March 8, 2023
The next generation virus-like particle platform for the treatment of peanut allergyJan M Sobczak, Pascal S Krenger, Federico Storni, et al.Allergy|July 18, 2025
The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based ApproachOliver Pfaar, Ralph Mösges, Michael S Blaiss, et al.Journal for Immunotherapy of Cancer|May 25, 2019
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.Journal for Immunotherapy of Cancer|April 28, 2019
Vaccination with nanoparticles combined with micro-adjuvants protects against cancerMona O Mohsen, Matthew D Heath, Gustavo Cabral-Miranda, et al.Allergy|July 8, 2025
Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field StudyJanice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, et al.The Journal of Allergy and Clinical Immunology|January 5, 2025
Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individualsJanice A Layhadi, Sviatlana Starchenka, Pieter-Jan De Kam, et al.The World Allergy Organization Journal|October 18, 2021
Dogmas, challenges, and promises in phase III allergen immunotherapy studiesPieter-Jan De Kam, Matthias F Kramer, Mohamed H Shamji, et al.Pageof 3